two separate class action lawsuits were filed against icn pharmaceuticals inc and its viratek inc subsidiary charging companies with disseminating allegedly false and misleading information regarding company drug virazole which being tested possible treatment for aids suit filed federal court behalf icn shareholders charges disclosures made icn over about past year encouraged investing public believe virazole was promising drug major importance and did not disclose serious adverse side effects court documents said icn spokesman declined comment lawsuits attorneys for plaintiffs were not immediately available for comment virazole also known ribavirin undergoing extensive testing possible treatment for aids related illnesses drug which available number countries outside united states has been approved fda for domestically aerosol form treatment for infection strikes young children called respiratory syncytial virus fda and house subcommittee conducting own separate probes into whether icn withheld data from fda adverse reactions antiviral drug securities and exchange commission also investigating company reuter 